BioPharma Credit Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Cash & Equivalents	12.59	5.62	135.05	120.53	94.71	Upgrade
Cash & Short-Term Investments	12.59	5.62	135.05	120.53	94.71	Upgrade
Cash Growth	123.97%	-95.84%	12.05%	27.26%	-51.00%	Upgrade
Accounts Receivable	53.46	31.71	20.23	19.73	9.59	Upgrade
Other Receivables	0.14	0.08	0.09	0.11	0.42	Upgrade
Receivables	53.6	31.8	20.32	19.84	10.01	Upgrade
Total Current Assets	66.19	37.42	155.37	140.37	104.72	Upgrade
Long-Term Investments	1,102	1,162	1,201	1,224	1,266	Upgrade
Total Assets	1,168	1,200	1,357	1,364	1,371	Upgrade
Accrued Expenses	17.56	16.94	15.87	24.35	6.34	Upgrade
Other Current Liabilities	-	0.95	-	1.95	-	Upgrade
Total Current Liabilities	17.56	17.88	15.87	26.3	6.34	Upgrade
Long-Term Unearned Revenue	-	0.06	-	0.26	0.56	Upgrade
Total Liabilities	17.56	17.94	15.87	26.56	6.9	Upgrade
Common Stock	13.74	13.74	13.74	13.74	13.74	Upgrade
Additional Paid-In Capital	607.13	607.13	607.13	607.13	607.13	Upgrade
Retained Earnings	530	560.81	720	716.59	742.85	Upgrade
Shareholders' Equity	1,151	1,182	1,341	1,337	1,364	Upgrade
Total Liabilities & Equity	1,168	1,200	1,357	1,364	1,371	Upgrade
Net Cash (Debt)	12.59	5.62	135.05	120.53	94.71	Upgrade
Net Cash Growth	123.97%	-95.84%	12.05%	27.26%	-51.00%	Upgrade
Net Cash Per Share	0.01	0.00	0.10	0.09	0.07	Upgrade
Filing Date Shares Outstanding	1,129	1,140	1,254	1,319	1,374	Upgrade
Total Common Shares Outstanding	1,129	1,186	1,303	1,319	1,374	Upgrade
Working Capital	48.63	19.53	139.5	114.06	98.38	Upgrade
Book Value Per Share	1.02	1.00	1.03	1.01	0.99	Upgrade
Tangible Book Value	1,151	1,182	1,341	1,337	1,364	Upgrade
Tangible Book Value Per Share	1.02	1.00	1.03	1.01	0.99	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.